CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $167,852 | -33.6% | 3,698 | -17.9% | 0.00% | -100.0% |
| Q2 2023 | $252,967 | -60.1% | 4,506 | -71.1% | 0.00% | -66.7% |
| Q4 2022 | $633,896 | -87.6% | 15,594 | -80.9% | 0.00% | -93.0% |
| Q1 2022 | $5,122,000 | +139.9% | 81,592 | +189.6% | 0.04% | +168.8% |
| Q4 2021 | $2,135,000 | +16.4% | 28,178 | +148.8% | 0.02% | -23.8% |
| Q2 2021 | $1,834,000 | -16.5% | 11,327 | -21.0% | 0.02% | -32.3% |
| Q4 2020 | $2,196,000 | +50.4% | 14,344 | -17.8% | 0.03% | +47.6% |
| Q3 2020 | $1,460,000 | +79.6% | 17,455 | +30.8% | 0.02% | -19.2% |
| Q4 2019 | $813,000 | – | 13,348 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |